Kenneth G. Saag, MD, MSc
Professor of Medicine and Epidemiology
Director, Center for Education and Research on Therapeutics of
Musculoskeletal Disorders
Division of Clinical Immunology and Rheumatology
University of Alabama at Birmingham
Birmingham, AL
Kenneth Saag, MD, MSc, is a Professor of Medicine in the Division of Clinical Immunology and Rheumatology at the University of Alabama at Birmingham (UAB) School of Medicine, and Professor of Epidemiology at the UAB School of Public Health. He is Director of the Deep South Musculoskeletal CERTs since its inception in 2000 and is Associate Director of the Multidisciplinary Clinical Research Center (NIAMS P60). Dr. Saag is a rheumatologist and outcomes researcher with expertise in MSD pharmacoepidemiology and clinical focus in bone health. He is the only rheumatologist on the Board of Directors of the National Osteoporosis Foundation. He is experienced in population-based investigations, working with large databases, and quality indicator development. Dr. Saag is on the US Food and Drug Administration Arthritis Advisory Committee and recently co-chaired the American Medical Association Physician Consortium for Performance Improvement on Osteoporosis. He is on the editorial board of Archives of Internal Medicine, Arthritis Care and Research, and Arthritis Research and Therapy. Dr. Saag has previously chaired the Arthritis Foundation Clinical, Therapeutics, and Outcomes Study Section, has served on several National Institutes of Health study sections, Institute of Medicine Committees, National Committees to develop both arthritis and osteoporosis guidelines, the Musculoskeletal Workgroup of the Cochrane Collaboration, and the National Committee for Quality Assurance workgroup on Arthritis Quality Indicators. Dr. Saag is Director of the Center for Outcomes, Effectiveness Research, and Education. He is also the American College of Rheumatology Quality of Care Committee Chair.
Dr. Saag reported that he serves as a consultant to Novartis Corporation; Savient Pharmaceuticals, Inc.; and Takeda Pharmaceuticals North America, Inc. He also reported that he serves as a contracted researcher for Novartis Corporation.
Dr. Saag reported that he serves as a consultant to Novartis Corporation; Savient Pharmaceuticals, Inc.; and Takeda Pharmaceuticals North America, Inc. He also reported that he serves as a contracted researcher for Novartis Corporation.